Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
3.
J Investig Med High Impact Case Rep ; 9: 23247096211009412, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33853424

RESUMO

A 67-year-old male was admitted with shortness of breath and diarrhea. His COVID-19 polymerase chain reaction test was positive, and he was found to be in acute heart failure. Troponin levels were elevated, echocardiogram showed ejection fraction of 24%, and his electrocardiogram was normal. Inflammatory markers were elevated. Further testing revealed suppressed thyroid-stimulating hormone and elevated free thyroxine (T4). Differential diagnosis at this point included possible myocarditis from the viral illness, exacerbation of heart failure from the viral infection or from thyrotoxicosis was considered. Patient's heart failure improved with initiation of heart failure therapies; however, biochemically, his thyroid function tests (TFTs) did not improve, despite empiric methimazole. Thyroid antibody tests were unremarkable. Thyroid ultrasound showed mildly enlarged thyroid gland with no increased vascularity and 5-mm bilateral cysts. Thyroid dysfunction was attributed to subacute thyroiditis from COVID-19, methimazole was tapered, and prednisone was initiated. The patient's TFTs improved. With the ongoing COVID-19 pandemic, it is imperative that clinicians keep a broad differential in individuals presenting with heart failure, and obtaining baseline TFTs may be reasonable. Rapid treatment of the underlying thyroiditis is important in these patients to improve the cardiovascular outcomes. In our experience, steroid therapy showed a rapid improvement in the TFTs.


Assuntos
COVID-19/complicações , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/diagnóstico , Tireoidite Subaguda/complicações , Tireoidite Subaguda/diagnóstico , Idoso , COVID-19/terapia , Diagnóstico Diferencial , Insuficiência Cardíaca/terapia , Humanos , Masculino , SARS-CoV-2 , Tireoidite Subaguda/tratamento farmacológico
4.
AACE Clin Case Rep ; 9(5): 178-179, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37736323
5.
Am J Med Sci ; 356(2): 181-184, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-30219161

RESUMO

Nonislet cell tumor hypoglycemia is rare. We highlight the diagnosis and treatment of recurrent severe hypoglycemia in a 49-year-old woman with malignant solitary fibrous tumor of the pleura (Doege-Potter syndrome). The clinical, laboratory and radiologic findings of the case are presented and a brief literature review is provided. Of note, imaging studies showed a large mass in the right hemithorax and pathology and immunehistochemical stains confirmed a malignant solitary fibrous tumor of the pleura. She was a poor surgical candidate owing to a large tumor burden. She was treated with a combination of temozolomide and bevacizumab to which she responded with resolution of hypoglycemia. The treatment of choice for hypoglycemia in patients with the Doege-Potter syndrome is surgical excision. We here report that a combination of temozolomide and bevacizumab may be a viable option in patients with inoperable disease.


Assuntos
Bevacizumab/efeitos adversos , Fibroma , Hipoglicemia/induzido quimicamente , Neoplasias Pleurais , Temozolomida/efeitos adversos , Bevacizumab/administração & dosagem , Feminino , Fibroma/diagnóstico , Fibroma/tratamento farmacológico , Humanos , Pessoa de Meia-Idade , Neoplasias Pleurais/diagnóstico , Neoplasias Pleurais/tratamento farmacológico , Temozolomida/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA